Current Oncology, Volume 26, Issue 1

A high prevalence of complementary and integrative medicine use is common for patients living with cancer. [...]

The legalization of medical assistance in dying (maid) in June 2016 expanded options for end-of-life care in Canada [...]

Cediranib, a potent inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor subunit B, and the c-Kit receptor tyrosine kinase, has shown antitumour activity as an antiangiogenic agent in preclinical model...

Human T cell lymphotropic virus 1 (htlv-1) is a bloodborne retrovirus that infects at least 5–20 million people around the world [...]

Bogdan Nowak sat in the waiting room anxiously clasping his knees. [...]

Purpose: Patient-reported symptom data are collected prospectively by a provincial cancer agency to mitigate the significant symptom burden that patients with cancer experience. However, an assessment of whether such symptom screening occurs uniforml...

Background: We examined the uptake of risk-reducing interventions, including bilateral mastectomy, risk-reducing salpingo-oophorectomy, oral contraceptive pills, tamoxifen, and raloxifene, for the entire population of women with a deleterious BRCA1 o...

Patient use of integrative oncology (the inclusion of nonconventional treatments alongside the conventional standard of care) continues to grow, with some studies showing its use in cancer patients to be as high as 91%. Naturopathic physicians are pr...

Background: Randomized controlled trials (rcts) provide limited evidence to support the use of survivorship care plans (scps), but they provide strong evidence for patient decision aids (ptdas). Despite that evidence, the uptake of ptdas has been lim...

Background: Exposing patients with metastatic colorectal cancer (MCRC) to all three active chemotherapeutic agents (oxaliplatin, irinotecan, fluorouracil) has improved survival. The benefit of second-line chemotherapy after a first-line triplet is no...